SCHEMBL201468

SCHEMBL201468

CCNC(=O)C(O)=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060269 0.78 MMP1 (0.48)
SCHEMBL3062032 0.78 ALDH1A1 (0.48)
SCHEMBL261066 0.77
SCHEMBL7826225 0.77
SCHEMBL688174 0.76
Hydrochloric Acid SCHEMBL725173 0.74
SCHEMBL1400059 0.72
Dimethylamine SCHEMBL9702699 0.72 MMP1 (0.39)
SCHEMBL5462094 0.72
SCHEMBL6910661 0.72 EGLN1 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283661-B1 PROCESS FOR LEACHING METAL SULFIDES WITH REAGENTS HAVING THIOCARBONYL FUNCTIONAL GROUPS JETTI RESOURCES LLC (US) 2024-06-05 EP claimed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
WO-2024094185-A1 NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF 药捷安康(南京)科技股份有限公司 2024-05-10 WO disclosed
US-10301272-B2 Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ] PHENEX PHARMACEUTICALS AG (DE) 2019-05-28 US disclosed
US-9353100-B2 Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections IDENIX PHARMACEUTICALS LLC (US) 2016-05-31 US disclosed
EP-2461811-B1 MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV IDENIX PHARMACEUTICALS LLC (US) 2016-04-20 EP disclosed
US-9284307-B2 Macrocyclic serine protease inhibitors IDENIX PHARMACEUTICALS LLC (US) 2016-03-15 US disclosed
EP-2387315-B1 IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150175562-A1 CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA] PHENEX PHARMACEUTICALS AG (DE) 2015-06-25 US disclosed
CN-1341593-A Proteinase inhibitor SMITHKLINE BEECHEM CORP (US) 2002-03-27 CN disclosed
US-6358955-B1 SCHIZOPHRENIA, PSYCHOLOGICAL DISORDERS, PARKINSON*S DISEASE; ANTIDEPRESSANTS NEUROGEN CORPORATION 2002-03-19 US disclosed
US-6069251-A HIGHLY SELECTIVE PARTIAL AGONISTS OR ANTAGONISTS AT BRAIN DOPAMINE RECEPTOR SUBTYPES OR PRODRUGS; DIAGNOSIS AND TREATMENT SCHIZOPHRENIA; ANTIDEPRESSANTS; CERTAIN MOVEMENT DISORDERS SUCH AS PARKINSONISM. NEUROGEN CORPORATION (US) 2000-05-30 US disclosed
CN-1207095-A Protease inhibitors SMITHKLINE BEECHAM CORP (US) 1999-02-03 CN disclosed
US-5712392-A DOPAMINERGIC AGENTS TREATING SCHIZOPHRENIA, ANTIDEPRESSANTS FOR PARKINSON'S DISEASE NEUROGEN CORPORATION (US) 1998-01-27 US disclosed
EP-0793653-A1 CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1997-09-10 EP disclosed
US-5656762-A TREATING SCHIZOPHRENIA, DEPRESSION, PARKINSON*S DISEASE NEUROGEN CORPORATION (US) 1997-08-12 US disclosed
US-5646281-A FOR USE IN THE DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA, DEPRESSION AND PARKINSON*S DISEASE NEUROGEN CORPORATION (US) 1997-07-08 US disclosed
US-5633377-A DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSON'SDISEASE NEUROGEN CORPORATION (US) 1997-05-27 US disclosed
WO-1996016040-A1 CERTAIN 4-AMINOMETHYL-2-SUBSTITUTED IMIDAZOLE DERIVATIVES AND 2-AMINOMETHYL-4-SUBSTITUTED IMIDAZOLE DERIVATIVES; NEW CLASSES OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1996-05-30 WO disclosed